

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

July 2021

Vol. 49, No. 7

CONTENTS

ARTICLES

- Multiple Computational Approaches for Predicting Drug Interactions with Human Equilibrative Nucleoside Transporter 1. *Siennah R. Miller, Thomas R. Lane, Kimberley M. Zorn, Sean Ekins, Stephen H. Wright, and Nathan J. Cherrington* **479**
- Assessment of the Potential for Veverimer Drug-Drug Interactions. *Dawn Parsell, Jun Shao, Robert Guttendorf, Vandana Mathur, Elizabeth Li, Yick Sen Wu, Li Tsao, Scott Tabakman, Yuri Stasiv, Angela Lee, Kalpesh Biyani, and Gerrit Klaerner . .* **490**
- Primary Human Hepatocyte Spheroids as an In Vitro Tool for Investigating Drug Compounds with Low Hepatic Clearance. *Julia Riede, Birgit M. Wollmann, Espen Molden, and Magnus Ingelman-Sundberg . . .* **501**
- Development and Verification of a Linked Δ^9 -THC/11-OH-THC Physiologically Based Pharmacokinetic Model in Healthy, Nonpregnant Population and Extrapolation to Pregnant Women. *Gabriela I. Patilea-Vrana and Jashvant D. Unadkat* **509**
- Preliminary Flow Modeling by Hybrid Automata Alternating Continuous Reaction and Discrete Transit for Pharmacokinetics. *Satoshi Koyama. . . .* **521**
- Improving the Translation of Organic Anion Transporting Polypeptide Substrates using HEK293 Cell Data in the Presence and Absence of Human Plasma via Physiologically Based Pharmacokinetic Modeling. *Christine M. Bowman, Buyun Chen, Jonathan Cheong, Liling Liu, Yuan Chen, and Jialin Mao* **530**
- Investigating the Utility of Humanized Pregnane X Receptor-Constitutive Androstane Receptor-CYP3A4/7 Mouse Model to Assess CYP3A-Mediated Induction. *Justin Q. Ly, Susan Wong, Liling Liu, Ruina Li, Kirsten Messick, and Jae H. Chang* **540**
- Evaluation of the Absorption, Metabolism, and Excretion of a Single Oral 1-mg Dose of Tropifexor in Healthy Male Subjects and the Concentration Dependence of Tropifexor Metabolism. *Lydia Wang-Lakshman, Zhuang Miao, Lai Wang, Helen Gu, Mark Kagan, Jessie Gu, Elizabeth McNamara, Markus Walles, Ralph Woessner, Gian Camenisch, Heidi J. Einolf, and Jin Chen.* **548**
- Hepatic Scaling Factors for In Vitro–In Vivo Extrapolation of Metabolic Drug Clearance in Patients with Colorectal Cancer with Liver Metastasis. *Areti-Maria Vasilogianni, Brahim Achour, Daniel Scotcher, Sheila Annie Peters, Zubida M. Al-Majdoub, Jill Barber, and Amin Rostami-Hodjegan* **563**
- Nonclinical Pharmacokinetics and Absorption, Distribution, Metabolism, and Excretion of Givosiran, the First Approved *N*-Acetylgalactosamine–Conjugated RNA Interference Therapeutic. *Jing Li, Ju Liu, Xuemei Zhang, Valerie Clausen, Chris Tran, Michael Arciprete, Qianfan Wang, Carrie Rocca, Li-Hua Guan, Guodong Zhang, Diana Najarian, Yuanxin Xu, Peter Smith, Jing-Tao Wu, and Saeho Chong* **572**
- A New Intestinal Model for Analysis of Drug Absorption and Interactions Considering Physiological Translocation of Contents. *Satoshi Asano, Aoi Yoshitomo, Shizuka Hozuki, Hiromi Sato, Yasuhiro Kazuki, and Akihiro Hisaka* **581**
- Comparative Proteomics Analysis of the Postmitochondrial Supernatant Fraction of Human Lens-Free Whole Eye and Liver. *Ankit Balhara, Abdul Basit, Upendra A. Argikar, Jennifer L. Dumouchel, Saranjit Singh, and Bhagwat Prasad* **592**

Supplemental material is available online at <http://dmd.aspetjournals.org>.

About the cover: Mizoribine mapped to the ENT1 ligand-based pharmacophore which was developed using data on ENT1 substrates. See the article Miller et al. ([dx.doi.org/10.1124/dmd.121.000423](https://doi.org/10.1124/dmd.121.000423)).